Mallinckrodt (NYSE: MNK) reported Q4 EPS of $1.84, $0.07 better than the analyst estimate of $1.77. Revenue for the quarter came in at $882.4 million versus the consensus estimate of $871.45 million.

"2015 was another pivotal year for Mallinckrodt. We were particularly pleased that fourth quarter and full year net sales were driven by volume growth," said Mark Trudeau, President and Chief Executive Officer. "Mallinckrodt's successful 'acquire to invest' growth strategy differentiates us from other specialty pharmaceutical companies as we typically focus on acquiring highly durable, under-resourced therapies that offer effective treatment alternatives for small, underserved and poorly penetrated patient populations."

"After acquiring assets, we enhance them with time-proven methods that have created value in the pharmaceutical industry for decades. We invest in manufacturing modernization, lifecycle management and label enhancement," Trudeau continued, "and, most importantly, we focus on generating strong clinical and health economic evidence to further emphasize the effectiveness of our products. With these investments, our goal is to improve patient outcomes, reach new patients in appropriate populations, and increase value for the healthcare system."

For earnings history and earnings-related data on Mallinckrodt (MNK) click here.